A study of a new drug combined with therapy for advanced digestive cancers
Part of Cancer, Digestive system clinical trials.
This study tests a new investigational drug (called SSGJ-706) combined with standard treatments for advanced cancers of the digestive system that have not been treated before. The goal is to see if the combination is safe and effective, potentially offering a new option for people with these cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a cancer of the digestive system (such as stomach, esophagus, colon/rectum, or pancreas) that has spread or cannot be removed with surgery.
- You have not received any prior systemic treatment (like chemotherapy or immunotherapy) for your advanced cancer.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are generally able to do your daily activities without needing help (ECOG 0-1).
- You are willing to provide a tumor tissue sample (or a stored sample) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called SSGJ-707 for people with colorectal cancer that has spread. It aims to see if the drug can help shrink or control the cancer.
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This trial tests a new drug called SSGJ-709 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called ASP2138 combined with chemotherapy and pembrolizumab for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. It may help if your tumor has certain markers (CLDN18.2 and PD-L1) and you haven't had prior chemotherapy for advanced disease.
This trial tests a new drug called SSGJ-706, either alone or with other treatments, for people with advanced non-small cell lung cancer (NSCLC) that has spread or cannot be surgically removed. The goal is to see if it helps shrink or control the cancer.
Hear when a new Gastric / Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.